Business Wire

Luxembourg Venture Days to Unite Investors, Startups and Innovators on 16 and 17 October 2024

Share

The second edition of the Luxembourg Venture Days will gather investors, startups, and innovators in a joint summit on 16 and 17 October 2024 at Luxexpo The Box. The annual event is organised by Luxembourg’s innovation agency Luxinnovation and the Luxembourg Private Equity and VC Association (LPEA) under the umbrella of Startup Luxembourg, the country’s network to promote its startup ecosystem. This event offers a unique opportunity for investors and startups to convene, exchange, liaise and explore new strategic and investment horizons.

Luxembourg’s stands as a pivotal financial hub offering various services that attract leading investors and markets around the world. It also built a robust, stable, diversified and thriving economy and is home to around 550 startups and 15 incubators, accelerators, and innovation hubs.

The country boasts a dynamic network of business angels, with a growing number of locally managed venture capital funds.

Luxembourg’s position within a 'Greater Region' (comprising bordering territories of France Germany and Belgium) with 12 million inhabitants, its agility and accessibility, coupled with its business-friendly climate, a pragmatic approach, and an easy access to key decision-makers, makes it a hub, bridge, and springboard for investors and startups in strategic and flourishing domains such as, fintech, space, climate, health, logistics, and mobility. It attracts and invites them to participate in shaping an ecosystem with international reach that inspires innovation and fosters sustainable growth.

The growing number of European unicorns (i.e. startups valued at one billion US dollars or more) shows the progress that the European startup ecosystem has made over the past years. Matchmaking platforms and networks that connect startups and investors are key to maintain and further accelerate this momentum. Luxembourg, as an international business hub and gateway at the heart of Europe, is well positioned to stimulate the interaction between investors and entrepreneurs.

“Luxembourg is a hub, bridge, and springboard for investors and startups to explore opportunities and forge partnerships in strategic domains,” says Sasha Baillie, CEO of Luxinnovation. “The Luxembourg Venture Days will bring together several renowned and high-level events under one roof. For startups, it will be an excellent opportunity to pitch in front of a variety of investors. For investors, it will be a place to team up and find new partners and investments. We are proud to join forces with these main actors to develop our new win-win event formula and foster Luxembourg’s role as a vibrant ecosystem, home and hub for startups and investors.”

“Luxembourg is an important hub for private equity and venture capital investors as it provides an agile and accessible platform for established actors and newcomers who want to keep abreast of developments, explore new avenues, grow their investments, and create added value,” adds Stephane Pesch, CEO of LPEA.”

Registration and agenda: Luxembourg Venture Days.

The highlights of Luxembourg Venture Days 2024:

  • Fit 4 Start pitching sessions (16 + 17 October)
    Pitch of 60 pre-selected startups and selection 20 for the next Fit 4 Start edition
  • LPEA annual Insights Conference (17 October)
    Full-day programme with panels and an exclusive pitching event
  • Keynote and masterclasses for investors and startups by US VC Jillian Manus (16 October)
  • Other pitch, demo, networking, and match-making sessions (16 + 17 October)
    • Tomorrow Street matchmaking breakfast with scale-ups (16 October)
    • Gener8tor Demo Day (17 October)
    • Luxembourg Business Angel Network (LBAN) reverse pitch (17 October)
    • Luxembourg Open Innovation Club (LOIC)/ Luxinnovation Reverse Pitch (16 October)
    • 8 pioneering startups to discover (17 October) – Lunch with eight Influential startups embodying our ecosystem’s potential
  • Presentation of the first-ever Dealroom report on EU-backed startups (16 October)
  • Presentation of the report “Titans of Tech” 2024 by European VC GP Bullhound (16 October)
    • Exclusive VC networking dinner (16 October)
  • Insightful panel discussions (16 + 17 October)
    • The value and benefits of investing in women-led startups (17 October)
    • Navigating term sheet negotiations with investors (16 October)
  • General closing ceremony (17 October) –- -Joint-programme for the large audience with:
    • Keynotes by several leading profiles, including Marjut Falkstedt, CEO of the European Investment Fund
    • Roundtable discussions
    • Announcement of the 20 startups selected for Fit 4 Start #15; followed by a networking cocktail.

About Luxinnovation: as the national innovation agency, we empower companies to innovate today to be ready for tomorrow. We contribute to the development of the economy as a whole by identifying innovation opportunities and fostering collaborative innovation projects that stimulate the development of a sustainable, competitive and digital economy. Set up as an Economic Interest Group, Luxinnovation is supported by the Ministry of the Economy, the Ministry for Research and Higher Education, the Ministry of Foreign and European Affairs, the Luxembourg Chamber of Commerce, the Luxembourg Chamber of Skilled Crafts and FEDIL – The Voice of Luxembourg’s Industry. www.luxinnovation.lu

The Luxembourg Private Equity and Venture Capital Association (LPEA) is the most trusted and relevant representative body of private equity and venture capital practitioners with a presence in Luxembourg. Created in 2010 by a leading group of private equity and venture capital players in Luxembourg, with more than 530 members today, LPEA plays a leading role locally actively promoting PE and VC in Luxembourg. LPEA provides a dynamic and interactive platform which helps investors and advisors to navigate through latest trends in the industry. www.lpea.lu

Startup Luxembourg is the unique brand of Luxembourg's startup ecosystem, aiming at showcasing its players and innovators inside and outside the country. This is a public initiative funded by the Ministry of the Economy and managed by Luxinnovation.
www.startupluxembourg.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241004816914/en/

Contacts

Jonas Mercier | Startup Luxembourg Coordinator |jonas.mercier@luxinnovation.lu |
T +352 43 62 63-858
Jean-Michel Gaudron | Head of Content Luxinnovation |
jean-michel.gaudron@luxinnovation.lu | T +352 43 62 63-684

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye